Compare Kroger Co (KR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Travere Therapeutics Inc. Common Stock — how do they compare? Kroger Co trades at $63.88 (market cap $35.87B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Kroger Co is far larger — about 7.4× Travere Therapeutics Inc. Common Stock's market cap, and Kroger Co pays a 2.57% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 109 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KR | TVTX | |
|---|---|---|
Market Cap | $35.87B | $4.88B |
Volume | 8,902,665 | 1,668,577 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $67.52 |
52-Week Low | $55.53 | $26.79 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $57.29B | $5.01B |
Dividend Yield | 2.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $63.09, up 0.85% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a low P/S of 0.26 and positive cash flow trends, though net income margin is thin at 0.73%. Recent news highlights digital growth and a strategic shift toward everyday low prices, while earnings have mostly beaten expectations.
Outlook is cautiously optimistic with a $70.62 consensus price target, but risks include integration challenges from acquisitions and cost pressures. The stock offers value with a dividend yield, yet investors should weigh slower sales guidance against operational improvements for near-term performance.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
